The research, led by a team at Beijing Children’s Hospital of Capital Medical University, analyzed data from 257 pediatric patients treated with sirolimus, drawing on a remarkable 766 to 892 blood samples collected during routine care. Rather than treating adverse reactions as isolated events, the investigators systematically quantified the relationship between steady-state trough concentrations of sirolimus, known as Cmin, and three of the drug’s most clinically significant toxicities: myelosuppression, abnormal liver function, and dyslipidemia. Trough concentrations, measured immediately before the next dose, are the standard metric for therapeutic drug monitoring of sirolimus, because the drug’s effects and toxicities track closely with whole-blood levels.

What makes the study methodologically distinctive is its pairing of two computational approaches that rarely meet in pharmacology. The first is Bayesian kernel machine regression, or BKMR, a flexible statistical framework originally developed to assess the health effects of complex environmental exposures such as air pollutant mixtures. BKMR excels at modeling nonlinear relationships and interactions among multiple simultaneous exposures without imposing rigid functional forms, which makes it well suited to the messy reality of pediatric drug monitoring, where age, weight, disease type, concomitant medications, and treatment duration all shift the toxicity landscape. The second component is a population pharmacokinetic model, or PopPK, which describes how sirolimus is absorbed, distributed, and cleared across a heterogeneous population of children and predicts individual exposure from dosing history and patient characteristics.

By integrating the two into a unified BKMR-PopPK framework, the researchers created something more powerful than either method alone. The PopPK model translates a proposed dose into a predicted trough concentration for a specific child, while the BKMR layer converts that predicted exposure into a quantified risk of myelosuppression, liver injury, or dyslipidemia. The result is a tool for model-informed precision dosing, an approach that replaces one-size-fits-all weight-based dosing with individualized regimens designed to keep each patient inside a safety window that is narrow enough to prevent toxicity but wide enough to control the underlying vascular lesion.

The analysis identified disease complexity and duration of therapy as key modifiers of risk. Children with complex or mixed vascular malformations faced different exposure-response relationships than those with simpler, more localized lesions, and the risks of certain toxicities grew as treatment extended over months. Based on these quantitative relationships, the team recommends routine trough concentration monitoring within two distinct safety windows: 5.0 to 7.5 nanograms per milliliter for children with simple lesions or milder disease, and 8.0 to 10.2 nanograms per milliliter for those with complex or mixed vascular malformations, who may require higher exposure to achieve disease control.

The temporal dimension of the findings carries particular weight for families and clinicians committed to long-term therapy. Sirolimus treatment for vascular anomalies often continues for a year or more, and the study’s results indicate that vigilance must intensify rather than relax as months accumulate. Beyond six months of treatment, the authors call for heightened surveillance for myelosuppression and dyslipidemia through regular screening of blood counts and lipid panels. This is a meaningful departure from practice patterns in which monitoring may become less rigorous once a patient has tolerated the drug through the early treatment period.

Each of the three adverse reactions examined carries its own clinical stakes. Myelosuppression, the suppression of bone marrow activity, can lower blood cell counts and increase vulnerability to infection, anemia, and bleeding. Abnormal liver function signals hepatotoxicity that, if unchecked, can progress to more serious injury. Dyslipidemia, the elevation of blood lipids, is subtler but consequential in children, because lipid abnormalities established early in life can seed long-term cardiovascular risk. By quantifying how each toxicity relates to trough concentration, the framework allows clinicians to weigh these distinct risks against the therapeutic benefit of suppressing the malformation itself.

The broader significance of the work extends beyond vascular anomalies. Rare pediatric diseases pose a persistent methodological dilemma: patient populations are small, clinical trials are difficult to mount, and safety data are often fragmentary or anecdotal. The authors argue that their integrated framework offers a template for extracting rigorous, quantitative safety insights from the routine clinical data that even small cohorts generate. In doing so, the study addresses a genuine knowledge gap. Prior research had suggested a strong link between sirolimus exposure and adverse reactions, but the quantitative relationship, the actual probabilities of toxicity at given concentrations, had remained undefined, leaving clinicians to rely on empirical dosing inherited from transplant medicine.

Therapeutic drug monitoring itself is not new to sirolimus; the drug’s narrow therapeutic index has long demanded blood level measurement. What is new is the precision with which those measurements can now be interpreted. Instead of a single broad target range applied to every child, the study supports disease-specific and time-dependent target ranges, embedded within a predictive model that can forecast an individual patient’s exposure and toxicity risk before a dose is even administered. The retrospective design, approved by the Institutional Ethics Committee of Beijing Children’s Hospital, means the findings will need prospective validation, but the sample size and the density of pharmacokinetic sampling lend the conclusions substantial credibility.

For the children who depend on sirolimus to shrink lesions that compress airways, deform faces, or bleed unpredictably, the study promises something deceptively simple: a better chance of staying on the drug long enough for it to work. Treatment discontinuation driven by adverse reactions is one of the most common reasons vascular anomaly therapy fails, and every avoidable discontinuation represents a child whose disease resumes its advance. By converting pharmacological data into individualized risk estimates and dosing guidance, the BKMR-PopPK framework moves pediatric vascular anomaly care a decisive step closer to the era of precision medicine, where the question is no longer simply how much drug to give, but how much drug this particular child can safely carry.

Subject of Research: Quantifying sirolimus exposure-response safety relationships in pediatric vascular anomalies using an integrated BKMR-PopPK framework

Article Title: Safety of sirolimus in pediatric vascular anomalies: a BKMR-PopPK exposure–response framework for individualized risk and dosing

Article References: Liu, B., Xu, X.-L., Wang, J.-L., Li, J., Wu, Y.-X., Zhang, X.-X., Liu, Q.-Y., Zhao, Y.-M., Guo, P., Zhang, R.-Q., Zhou, H., Mao, X.-T., Jia, Y.-M., Cheng, X.-L., Wang, S.-C., & Wang, X.-L. (2026). Safety of sirolimus in pediatric vascular anomalies: a BKMR-PopPK exposure–response framework for individualized risk and dosing. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01076-9

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01076-9

Keywords: sirolimus, vascular anomalies, pediatrics, adverse drug reactions, therapeutic drug monitoring, population pharmacokinetics, Bayesian kernel machine regression, precision dosing, myelosuppression, dyslipidemia, liver function, rare diseases

The research team, led by Frederick Ifijeh of Management Sciences for Health in Abuja, together with colleagues from Asaba Specialist Hospital and the Ogun State Ministry of Health, designed the study as a sequential explanatory mixed-methods cross-sectional investigation. Between September and October 2025, the team covered all 490 functional public health facilities in Ogun State, a comprehensive sampling frame that gives the results unusual breadth for a study of this kind. The quantitative component captured 404 healthcare workers through structured questionnaires administered with KoboCollect, a mobile data collection platform built on the Open Data Kit framework. The qualitative component then followed up with 162 key informants, drawn from the same facilities, whose interviews allowed the researchers to probe the reasons behind the statistical patterns.

The headline number is stark: of the 404 healthcare workers who completed the survey, only 23, or 5.4 percent, had ever reported an adverse drug reaction in their careers. This is not merely a matter of low enthusiasm. The researchers are careful to note that because so few respondents had actually reported, the events-per-variable ratios in their regression models fell below conventional statistical thresholds, meaning the regression estimates should be read as exploratory rather than definitive. This methodological honesty matters, because it signals to readers that the true drivers of reporting behavior are best understood by triangulating the survey data with the qualitative interviews rather than relying on odds ratios alone.

Even with that caveat, the quantitative signals were consistent across both bivariate tests and multivariable logistic regression. Three factors stood out repeatedly: whether a worker had completed an adverse drug reaction reporting form before, whether suspected reactions were routinely documented in patient case notes, and whether the worker knew the channels through which reports should be submitted. In the exploratory consolidated model, routine documentation of suspected reactions, knowledge of reporting forms, time constraints, and perceived reporting burden all remained significant predictors of reporting practice. In other words, the workers most likely to report were those for whom adverse drug reaction documentation had been woven into their everyday clinical routines, and who had the practical tools and knowledge to act on a suspicion when it arose.

The qualitative interviews with 162 key informants added a sobering institutional dimension to these findings. Most informants reported receiving no pharmacovigilance training in the preceding two years, and nearly half indicated that no formal adverse drug reaction reporting system existed in their facilities at all. This is a critical distinction that the study’s authors emphasize: underreporting in Ogun State is not primarily a problem of individual motivation or ignorance among clinicians. It is a problem of infrastructure. A healthcare worker cannot file a report if the facility has no reporting forms, no designated focal person to receive them, and no established pathway to the national regulator.

Thematic analysis of the interviews, following the framework developed by Braun and Clarke, identified four principal barriers. The first is limited pharmacovigilance knowledge, meaning many workers simply do not recognize when a patient’s symptom cluster constitutes a suspected adverse reaction worth flagging. The second is weak or absent reporting systems at the facility level, which renders even well-informed workers powerless to act. The third is inadequate training and supervision, with frontline staff left without refresher courses, supportive oversight, or standard operating procedures to guide them. The fourth comprises patient-related barriers to detection, including patients who do not mention symptoms they attribute to malaria itself, who discontinue treatment without follow-up, or who seek care from informal providers outside the reporting system entirely.

The structural diagnosis has significant implications for Nigeria’s national pharmacovigilance architecture, which centers on the National Agency for Food and Drug Administration and Control, known as NAFDAC, and the National Malaria Elimination Programme. Spontaneous reporting systems depend on a chain that runs from the bedside to the regulator: a clinician must suspect a reaction, document it, complete a form, transmit it through a facility or district focal person, and eventually receive feedback confirming that the report was received and acted upon. The study suggests that in Ogun State this chain is broken at multiple links simultaneously. Without feedback from regulators, even motivated reporters receive no signal that their efforts matter, which is a well-known cause of reporting fatigue in pharmacovigilance systems worldwide.

What makes the study particularly valuable is its insistence that awareness campaigns alone will not solve the problem. The authors argue that improving adverse drug reaction reporting requires more than telling healthcare workers that reporting is important. It requires operational support: routine supervision visits, designated pharmacovigilance focal persons in every facility, consistent availability of reporting tools, and functional feedback mechanisms that close the loop between frontline reporters and the national system. Integrating adverse drug reaction documentation into routine case note workflows, so that recording a suspected reaction becomes as habitual as recording a temperature, emerges from the data as one of the most promising single interventions.

The context of malaria treatment makes these gaps especially consequential. Artemisinin-based combination therapies are administered to millions of Nigerians each year, and the emergence of drug resistance or previously unrecognized safety signals would first appear as patterns in adverse event data. If 94.6 percent of frontline providers have never filed a single report, the national surveillance system is effectively operating with a fraction of the sensitivity it needs. The authors note that underreporting driven by system-level constraints, including the lack of reporting forms, the absence of trained focal persons, weak supervision, and limited feedback from regulators, is likely to yield the greatest gains when those systems are strengthened, rather than when individual workers are exhorted to try harder.

For policymakers across malaria-endemic countries, the Ogun State findings offer a replicable template. The combination of a facility-wide quantitative survey with a large qualitative informant pool allowed the researchers to move beyond describing how rarely reporting happens and toward explaining why. The answer, in this setting, is that pharmacovigilance has been treated as an individual responsibility without being supported as an institutional function. Reversing that imbalance, through trained focal persons, reliable forms, embedded documentation routines, and visible feedback from NAFDAC and partner programs, would transform adverse drug reaction reporting from an occasional act of individual initiative into a routine, self-sustaining part of malaria case management, and would give Nigeria’s medicine safety system the early-warning capability its treatment scale demands.

Subject of Research: Determinants of adverse drug reaction reporting for antimalarial medicines among healthcare workers in Ogun State, Southwest Nigeria

Article Title: Determinants of adverse drug reaction reporting for antimalarial medicines: a mixed-methods study among healthcare workers in ogun State Southwest Nigeria

Article References: Ifijeh, F., Ejiyere, H., Babarinde, T., Adenekan, O. J., Otohabru, B., Adejo, I., Chukwuji, C., & Uko, I. (2026). Determinants of adverse drug reaction reporting for antimalarial medicines: a mixed-methods study among healthcare workers in ogun State Southwest Nigeria. BMC Health Services Research. https://doi.org/10.1186/s12913-026-15598-5

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15598-5

Keywords: adverse drug reactions, pharmacovigilance, antimalarial medicines, malaria, healthcare workers, Nigeria, drug safety, health systems, mixed-methods research, reporting barriers, artemisinin-based combination therapies, NAFDAC

Hand-foot syndrome, or PPE, is far more than a cosmetic nuisance. The condition typically begins with tingling, numbness and redness on the palms of the hands and soles of the feet, and can progress in severe cases to swelling, blistering, ulceration and intense pain that makes walking, gripping objects or even buttoning a shirt difficult. Because these symptoms strike exactly the functions patients rely on for daily life, PPE is a leading cause of dose reductions, treatment interruptions and outright abandonment of otherwise effective cancer regimens. Oncologists have long recognized it as a hallmark toxicity of certain targeted therapies and chemotherapy agents, but the true breadth of drugs implicated — and the timing of onset — has remained surprisingly poorly mapped.

To build that map, the researchers turned to FAERS, the FDA’s sprawling spontaneous reporting database, which collects adverse event submissions from healthcare professionals, manufacturers and patients across the United States. They extracted reports spanning the first quarter of 2004 through the first quarter of 2025, removed duplicate submissions, and then applied a family of statistical techniques known as disproportionality analysis. Rather than proving causation in the way a clinical trial would, disproportionality analysis asks a subtler question: does a particular drug appear in reports of a given side effect more often than would be expected by chance? Four complementary algorithms were used to answer that question — the reporting odds ratio, the proportional reporting ratio, the Bayesian confidence propagation neural network and multi-gamma Poisson shrinkage. Requiring agreement across all four methods helps filter out spurious associations that can arise in self-reported data.

The results were striking in both their scale and their specificity. Protein kinase inhibitors — the targeted drugs that block enzymes driving cancer cell growth and tumor blood vessel formation — and antimetabolites, the classic chemotherapy agents that interfere with DNA and RNA synthesis, emerged as the dominant drug classes. Among individual agents, the oral kinase inhibitor regorafenib, the multi-kinase blocker sorafenib and the fluoropyrimidine prodrug capecitabine produced the strongest safety signals. These three drugs are mainstays of treatment for colorectal cancer, hepatocellular carcinoma, renal cell carcinoma and other hard-to-treat malignancies, meaning the toxicity burden is concentrated in some of oncology’s most vulnerable populations. The finding that hundreds of other drugs also appeared in PPE reports underscores that the syndrome is not confined to a short list of notorious culprits.

Perhaps the most clinically actionable discovery concerns timing. The vast majority of PPE cases — 83.4 percent — occurred within the first 90 days of starting treatment, with many surfacing within the initial weeks. This early-onset pattern carries an important message for oncology teams: the highest-risk window for hand-foot syndrome opens almost immediately after a patient begins therapy. The authors argue that this argues for proactive patient education at the very first prescription, so that patients recognize the earliest tingling or redness and report it before it escalates into blistering lesions. It also supports intensified skin assessment during the initial phases of treatment with high-risk drugs, when a timely dose adjustment can often prevent progression without compromising cancer control.

The analysis also uncovered differences in reporting patterns between female and male patients. For two drugs in particular — the HER2-targeted breast cancer therapy lapatinib and capecitabine — PPE signals were stronger in women. The researchers are careful to caution against overinterpreting this finding. Sex-related differences in spontaneous reports can arise from prescribing patterns, with some drugs used predominantly in diseases that affect one sex more than the other, as well as from possible biological factors such as differences in skin structure, drug metabolism or hormonal influences. Disentangling genuine biological susceptibility from the artifacts of who receives which drug and who reports which symptom remains an open challenge for pharmacovigilance, and the authors explicitly call for cautious interpretation and further study.

Mechanistically, hand-foot syndrome is thought to arise from the unique biology of the skin on the palms and soles. These regions are rich in eccrine sweat glands, experience high mechanical pressure and friction, and express high levels of the molecular targets — such as vascular endothelial growth factor receptor and platelet-derived growth factor receptor — that protein kinase inhibitors are designed to block. When those signaling pathways are inhibited in the skin’s blood vessels, capillary damage and local inflammation can follow, and the repeated trauma of walking and gripping amplifies the injury. For antimetabolites like capecitabine, which is converted to 5-fluorouracil inside the body, the toxicity reflects the drug’s interference with rapidly dividing cells, with the concentration of the activating enzyme thymidine phosphorylase particularly high in palm and sole tissue. The convergence of drug exposure and mechanical stress explains why the syndrome has such a distinctive anatomical fingerprint.

The scale of the new study gives it particular weight in a field where much of the evidence comes from small clinical trials that may not capture rare or slowly accumulating toxicities. By pooling more than two decades of real-world reports, the analysis captures the experience of a far more diverse patient population than any single trial — patients with comorbidities, concurrent medications and varying ethnic backgrounds. At the same time, the authors and pharmacovigilance experts alike emphasize the inherent limitations of spontaneous reporting: not all adverse events are reported, reporting rates are influenced by media attention and litigation, and the database cannot establish how frequently PPE occurs relative to the total number of patients treated. Disproportionality signals are a starting point for hypothesis generation, not a verdict on causation.

Even with those caveats, the study’s implications for clinical practice are concrete. Oncologists prescribing regorafenib, sorafenib or capecitabine now have robust, data-driven backing for early and sustained skin monitoring, and the identification of 427 drugs with PPE reports should prompt awareness beyond the usual suspects, particularly as newer kinase inhibitors reach the market. For patients, the message is empowering: symptoms in the hands and feet during cancer treatment should never be dismissed as minor, because early recognition opens the door to dose modification, topical therapies, cooling measures and supportive care that can keep treatment on track. The research team concludes that enhanced vigilance and tailored monitoring schedules — matched to each drug’s risk profile and to the early onset window — are the most promising route to reducing the burden of this debilitating toxicity while preserving the anticancer benefits of the drugs patients depend on.

Subject of Research: Drug-induced palmar-plantar erythrodysaesthesia syndrome associated with antineoplastic agents identified through FDA adverse event reporting data

Article Title: Antineoplastic agent-induced palmar-plantar erythrodysaesthesia syndrome: insights from the FDA adverse event reporting system

Article References: Cheng, H., Li, Q., Hong, X., Zhang, Z., Chen, L., Yang, X., Wang, S., & Pan, W. (2026). Antineoplastic agent-induced palmar-plantar erythrodysaesthesia syndrome: insights from the FDA adverse event reporting system. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06547-0

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06547-0

Keywords: hand-foot syndrome, palmar-plantar erythrodysaesthesia, FAERS, pharmacovigilance, protein kinase inhibitors, capecitabine, regorafenib, sorafenib, antineoplastic agents, disproportionality analysis, adverse drug reactions, oncology

Adalimumab, marketed under the name Humira, has been used extensively for conditions like rheumatoid arthritis, Crohn’s disease, and psoriasis, among others. However, recent investigations underscore a nuanced aspect of adalimumab therapy—the concept of immunogenicity. Immunogenicity refers to the ability of a substance, such as a drug, to provoke an immune response. In the context of adalimumab, certain patients develop anti-drug antibodies that can significantly reduce the drug’s efficacy and potentially lead to adverse reactions. This phenomenon raises important questions about the long-term management and effectiveness of adalimumab in patients with noninfectious uveitis.

The study conducted by Han et al. emphasizes the importance of TDM in managing therapeutic regimens for patients suffering from noninfectious uveitis. Therapeutic drug monitoring allows healthcare providers to evaluate drug levels in the bloodstream and make informed decisions regarding dosage adjustments. This is particularly pivotal in conditions where maintaining adequate drug levels is essential for disease control. The research illustrates that subtherapeutic levels often correlate with poor patient outcomes, while therapeutic levels can provide significant relief from symptoms and disease progression.

Noninfectious uveitis, often characterized by inflammation of the uvea, can lead to severe complications, including vision loss. The immunological component of this condition is complex, as it involves a delicate balance between the body’s immune response and the potential for self-damage. Adalimumab is designed to target and inhibit tumor necrosis factor-alpha (TNF-α), a key cytokine involved in the inflammatory process, thus playing a vital role in the management of uveitis. The study’s focus on the immunogenicity of adalimumab further complicates this picture, as the emergence of antibodies against the drug can lead to inadequate therapy and exacerbation of symptoms.

The findings of the study are crucial, especially given the growing incidence of noninfectious uveitis and its debilitating effects. By employing TDM, healthcare professionals can tailor treatment strategies that account for individual variations in drug metabolism and immune response. The study conducted by Han et al. presents compelling evidence that supports the argument for adopting routine TDM in clinical practice to enhance the management of patients receiving adalimumab.

Moreover, the nuances of immunogenicity in adalimumab therapy extend beyond mere semantics. They indicate a shift toward safer, more effective personalized medicine. This approach considers the unique immune profiles of patients and potentially addresses the root causes of treatment failures. Evaluating the immunogenic potential of biological medications is crucial for ensuring that patients derive maximum benefit from these therapies while minimizing risks.

As clinical practices evolve, the integration of immunogenicity studies into routine assessments can transform the standard of care for patients suffering from chronic autoimmune conditions. This could lead to the development of predictive markers that can help anticipate which patients are at risk of developing anti-drug antibodies. Such advancements will not only foster better management of medications but could also potentially lead to breakthroughs in drug formulation.

Examining the intersection of immunogenicity and therapeutic drug monitoring opens a new dialogue within the regulatory frameworks that govern drug approvals. Pharmaceutical companies are now challenged to include thorough immunogenicity assessments in their development pipelines. This comprehensive approach not only addresses safety concerns but also enhances the therapeutic landscape for patients worldwide.

It is also essential to recognize that the journey of implementing routine TDM and addressing immunogenicity is fraught with challenges. Health care providers face practical hurdles, including the availability of resources for frequent monitoring and the need for robust protocols to interpret the data obtained. However, the long-term benefits in terms of patient outcomes and reduced healthcare costs present a compelling case for overcoming these obstacles.

As the landscape of autoimmune disease treatment evolves, studies like that of Han et al. herald promising advancements in our understanding of drug therapy and immunogenicity. The intersection of TDM and immunogenicity underscores the critical need for ongoing research and investment in patient-centered strategies that enhance therapeutic efficacy. Focused efforts in this area could pave the way for more personalized approaches to treating complex medical conditions.

In conclusion, the findings of Han et al. serve as a pivotal reminder of the importance of continued exploration and innovation in the field of immunology. By harnessing the power of therapeutic drug monitoring and deepening our understanding of immunogenicity, we can make strides toward improving patient care in noninfectious uveitis and beyond. The future is bright, and continued research endeavors will undoubtedly shape the landscape of autoimmune disease management for years to come.

Subject of Research: Immunogenicity of Adalimumab in Patients with Noninfectious Uveitis based on Therapeutic Drug Monitoring

Article Title: Immunogenicity of adalimumab in patients with noninfectious uveitis based on therapeutic drug monitoring.

Article References: Han, JW., Zhou, Y., Guo, J. et al. Immunogenicity of adalimumab in patients with noninfectious uveitis based on therapeutic drug monitoring. J Transl Med 23, 1232 (2025). https://doi.org/10.1186/s12967-025-07352-y

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12967-025-07352-y

Keywords: Immunogenicity, therapeutic drug monitoring, adalimumab, noninfectious uveitis, personalized medicine.